Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Dec 20, 2024, 4:00 PM
1.810
+0.020 (1.12%)
After-hours: Dec 20, 2024, 7:55 PM EST
Fractyl Health Revenue
Fractyl Health had revenue of $14.00K in the quarter ending September 30, 2024, a decrease of -61.11%. This brings the company's revenue in the last twelve months to $97.00K, down -14.16% year-over-year. In the year 2023, Fractyl Health had annual revenue of $120.00K.
Revenue (ttm)
$97.00K
Revenue Growth
-14.16%
P/S Ratio
n/a
Revenue / Employee
$951
Employees
102
Market Cap
86.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 120.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 55.75M |
LENSAR | 48.87M |
Coya Therapeutics | 9.55M |
Cibus | 4.15M |
Adagene | 815.75K |
Monogram Technologies | 365.00K |
GUTS News
- 9 days ago - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 12 days ago - Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 25 days ago - Fractyl Health to Participate in the Upcoming December Conferences - GlobeNewsWire
- 5 weeks ago - Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 - GlobeNewsWire
- 7 weeks ago - Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 - GlobeNewsWire
- 7 weeks ago - Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024 - GlobeNewsWire